Lipoprotein(a), commonly referred to as Lp(a), has emerged as a significant focus in cardiovascular health discussions. First identified in 1963, Lp(a) has gained attention in recent years due to its association with heart disease risk. Cardiologists, including Dr. Ahmet Afsin Oktay, emphasize the importance of measuring Lp(a) levels for a more personalized risk assessment of cardiovascular diseases.
Structurally similar to low-density lipoprotein (LDL), Lp(a) is considered "bad" cholesterol due to its role in plaque formation in arteries, contributing to atherosclerosis. Research indicates that elevated Lp(a) levels are linked to various cardiovascular conditions, including heart attacks and strokes. Unlike other cholesterol forms, Lp(a) levels are primarily determined by genetics, with approximately 20% of the global population exhibiting high levels.
Routine cholesterol tests do not typically measure Lp(a), but a specific blood test can identify its levels without requiring fasting. Current guidelines recommend that adults have their Lp(a) checked at least once in their lifetime. Normal levels are defined as less than 30 mg/dL, while levels above 50 mg/dL are considered high.
Currently, there is no dedicated medication to reduce Lp(a) levels; thus, management focuses on overall cardiovascular risk factors, such as high blood pressure and diabetes. Lifestyle modifications, including a healthy diet and regular exercise, remain essential in reducing heart disease risk.
Future developments in Lp(a) treatment may include targeted therapies currently under investigation, which aim to address the production of Lp(a) directly. This evolving landscape of understanding and potential treatment options underscores the growing recognition of Lp(a) in cardiovascular health.